<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Optical Genome Mapping - Zeid Hamadeh</title>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600&display=swap" rel="stylesheet">
    
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        :root {
            --text-primary: #0a0a0a;
            --text-secondary: #525252;
            --text-tertiary: #a3a3a3;
            --border: #e5e5e5;
            --bg: #ffffff;
        }

        body {
            font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
            line-height: 1.65;
            color: var(--text-primary);
            background: var(--bg);
            -webkit-font-smoothing: antialiased;
        }

        nav {
            position: fixed;
            top: 0;
            width: 100%;
            background: rgba(255, 255, 255, 0.9);
            backdrop-filter: blur(20px);
            border-bottom: 1px solid var(--border);
            z-index: 1000;
        }

        .nav-container {
            max-width: 960px;
            margin: 0 auto;
            padding: 1.25rem 2rem;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }

        .logo {
            font-weight: 500;
            font-size: 1rem;
            color: var(--text-primary);
            text-decoration: none;
        }

        .nav-links {
            display: flex;
            gap: 2rem;
            list-style: none;
        }

        .nav-links a {
            color: var(--text-secondary);
            text-decoration: none;
            font-size: 0.9rem;
            transition: color 0.2s;
        }

        .nav-links a:hover {
            color: var(--text-primary);
        }

        .container {
            max-width: 720px;
            margin: 0 auto;
            padding: 0 2rem;
        }

        article {
            padding: 140px 0 100px;
        }

        .article-meta {
            font-size: 0.8125rem;
            color: var(--text-tertiary);
            text-transform: uppercase;
            letter-spacing: 0.08em;
            margin-bottom: 1rem;
            font-weight: 500;
        }

        h1 {
            font-size: 2.5rem;
            font-weight: 500;
            line-height: 1.2;
            margin-bottom: 1rem;
            letter-spacing: -0.02em;
        }

        .article-subtitle {
            font-size: 1.25rem;
            color: var(--text-secondary);
            margin-bottom: 3rem;
            font-weight: 300;
        }

        .article-content p {
            margin-bottom: 1.5rem;
            line-height: 1.8;
            color: var(--text-secondary);
        }

        .article-content h2 {
            font-size: 1.75rem;
            font-weight: 500;
            margin-top: 3rem;
            margin-bottom: 1.5rem;
            color: var(--text-primary);
        }

        .article-content h3 {
            font-size: 1.375rem;
            font-weight: 500;
            margin-top: 2.5rem;
            margin-bottom: 1rem;
            color: var(--text-primary);
        }

        .article-content ul {
            margin: 1.5rem 0;
            padding-left: 1.5rem;
        }

        .article-content li {
            margin-bottom: 0.75rem;
            line-height: 1.7;
            color: var(--text-secondary);
        }

        .article-content strong {
            color: var(--text-primary);
            font-weight: 600;
        }

        .back-link {
            display: inline-block;
            margin-top: 4rem;
            color: var(--text-secondary);
            text-decoration: none;
            font-size: 0.9rem;
            transition: color 0.2s;
        }

        .back-link:hover {
            color: var(--text-primary);
        }

        footer {
            padding: 3rem 0;
            border-top: 1px solid var(--border);
            text-align: center;
        }

        footer p {
            color: var(--text-tertiary);
            font-size: 0.875rem;
        }

        @media (max-width: 768px) {
            article {
                padding: 120px 0 80px;
            }

            h1 {
                font-size: 2rem;
            }

            .article-subtitle {
                font-size: 1.125rem;
            }
        }
    </style>
</head>
<body>
    <nav>
        <div class="nav-container">
            <a href="../index.html" class="logo">Zeid Hamadeh</a>
            <ul class="nav-links">
                <li><a href="../index.html">Home</a></li>
                <li><a href="../index.html#research">Research</a></li>
                <li><a href="../index.html#writing">Writing</a></li>
            </ul>
        </div>
    </nav>

    <div class="container">
        <article>
            <div class="article-meta">Clinical Project · Lead Investigator</div>
            <h1>Clinical Implementation of Optical Genome Mapping at VGH</h1>
            <p class="article-subtitle">Establishing OGM as a Front-Line Diagnostic for Hematologic Neoplasms</p>

            <div class="article-content">
                <h3>Overview</h3>
                <p>As project lead at Vancouver General Hospital’s Cytogenomics Laboratory, I directed the <strong>clinical validation, implementation, and launch</strong> of <strong>Optical Genome Mapping (OGM)</strong> as a first-line diagnostic test for hematological malignancies. This initiative, completed in <strong>November 2023</strong>, represents the <strong>first clinical deployment of OGM in Canada</strong> for acute leukemia testing and has since become an integral part of routine diagnostics at VGH.</p>

                <h3>Validation and clinical impact</h3>
                <ul>
                    <li>Led the <strong>validation and clinical roll-out</strong> of OGM as a front-line diagnostic tool for acute leukemias.</li>
                    <li>Since implementation, the lab has profiled <strong>hundreds of patients</strong> with a <strong>97% quality control success rate</strong> and <strong>clinically significant findings in 49%</strong> of cases—directly influencing diagnostic and treatment decisions.</li>
                    <li>Presented findings demonstrating that OGM consistently detects <strong>clinically actionable structural variants</strong> missed by conventional cytogenetic methods.</li>
                </ul>

                <h3>Dissemination and recognition</h3>
                <p>
                    The project’s validation and clinical impact have been widely disseminated through national and international platforms, establishing VGH as a Canadian leader in genomic innovation. 
                    It was also featured in the 
                    <a href="https://file.pathology.ubc.ca/PathAnnualReport2023.pdf" target="_blank">
                        2023 UBC Department of Pathology & Laboratory Medicine Annual Report
                    </a>, 
                    highlighting its role in advancing genomic diagnostics in British Columbia.
                </p><ul>
                    <li><strong>2023 Canadian College of Medical Geneticists (CCMG)</strong> Annual Scientific Conference – Oral and poster presentations</li>
                    <li><strong>2023 Cancer Genomics Consortium (CGC)</strong> – Poster presentation</li>
                    <li><strong>2023 American Society of Hematology (ASH)</strong> – Poster presentation</li>
                    <li><strong>2024 American College of Medical Genetics (ACMG)</strong> – Platform presentation</li>
                    <li>Abstracts accepted for <strong>2024 CCMG</strong> and <strong>2024 CGC</strong>, under review for <strong>2024 European Society of Human Genetics (ESHG)</strong></li>
                </ul>

                <h3>Publications and ongoing work</h3>
                <ul>
                    <li>Preparing a <strong>peer-reviewed manuscript</strong> detailing the clinical validation and diagnostic impact of OGM in hematologic neoplasms.</li>
                    <li>Expanding testing to include <strong>myelodysplastic syndromes</strong>, <strong>relapsed acute leukemias</strong>, and <strong>chronic lymphocytic leukemia</strong>.</li>
                    <li>Integrating OGM with <strong>Oxford Nanopore long-read sequencing</strong> for comprehensive structural variant characterization.</li>
                </ul>

                <h3>Impact and significance</h3>
                <p>This project has established a new clinical standard for detecting complex structural variants in hematologic malignancies. OGM now serves as a routine first-line diagnostic at VGH, streamlining turnaround times and providing higher-resolution insights than traditional cytogenetic testing. Ongoing efforts continue to expand the technology’s scope and demonstrate its potential as a cornerstone of precision oncology in Canada.</p>
            </div>

            <a href="../index.html#research" class="back-link">← Back to Research</a>
        </article>
    </div>

    <footer>
        <div class="container">
            <p>© 2025 Zeid Hamadeh</p>
        </div>
    </footer>
</body>
</html>